Incyte (Nasdaq: INCY) presented Phase 1/2 multidose data for its investigational drug latarcibart (VGA039) at the 34th Congress of the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE